Ranula treated using sclerotherapy with OK-432

DOI
  • Toge Sakiko
    Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
  • Iuchi Hiroyuki
    Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
  • Kawabata Masaki
    Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
  • Miyashita Keiichi
    Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University
  • Yamashita Masaru
    Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University

Bibliographic Information

Other Title
  • OK-432による硬化療法を行ったガマ腫4例

Search this article

Description

OK-432 （PicibanilⓇ） is a penicillin-inactivated, low-toxicity strain of group A Streptococcus. It is widely used in Japan as an immunotherapeutic agent for malignant tumors. Sclerotherapy with OK-432 is recommended as the optimal treatment for ranula because it is minimally invasive and safe. This study reports four patients with shrunken ranula treated with OK-432 local injection therapy. In three cases, the content of the ranula was aspirated to the maximum extent possible, and then a volume of the OK-432 solution equal to the aspirated volume was injected. In one case, the OK-432 solution was injected at a high concentration without aspirating the contents of the ranula. All cases were followed up using ultrasonography. After 6 weeks, all cases showed shrinkage of the ranula. In one case, a re-enlargement of the ranula was observed 5 months after post-injection, but it resolved spontaneously after 4 months. Eventually, disappearance of the ranula was noted in all cases. Adverse effects, including fever lasting for 2-3 days （3/4 cases） and local swelling for 3-5 days （2/4 cases）, were identified. Sclerotherapy with OK-432 appears to be an effective and safe treatment and may be the first choice for ranula before considering surgery.

Journal

  • Stomato-pharyngology

    Stomato-pharyngology 36 (1), 59-64, 2023

    Japan Society of Stomato-pharyngology

Keywords

Details 詳細情報について

Report a problem

Back to top